Anchored in the findings of one of the founders while working at Columbia University and since licensed from that institution, Forkhead BioTherapeutics is an early stage regenerative medicine company and biotechnology company structured around advancing to use-condion their transformational oral therapy for insulin-dependent diabetes. Previous investigation has demonstrated ability to achieve targeted suppression of Foxo1, a nuclear transcription factor, to transform cells in the gut into glucose regulated insulin producing cells. The declared objective is to exploit this discovery by developing an oral agent -- a pill -- to treat insulin-dependent diabetes by restoring normal glucose metabolism.
